Talk:Baricitinib

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Chemicals C‑class Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
C	This article has been given a rating which conflicts with the project-independent quality rating in the banner shell. Please resolve this conflict if possible.
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Baricitinib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Can we relate the structure to its pharmacological properties

Which groups make it a jak inhibitor, and what do the other parts of the molecule do ? - Rod57 (talk) 11:48, 27 April 2016 (UTC)[reply]

Needs summary of clinical trials, side-effects etc

FDA Says 'No' to Baricitinib for Rheumatoid Arthritis - Dosages and safety were noted as concerns mentions both. EU likely to approve both 2mg and 4mg/day? but FDA didn't like either dose. - Rod57 (talk) 12:13, 18 April 2017 (UTC)[reply]

Another possible use

"in vivo administration of baricitinib, an inhibitor of Janus kinases 1 and 2 (JAK1/JAK2) which are downstream of IFNGR and IL6R, also prevents GvHD while preserving GvL in our preclinical murine model." (https://ashpublications.org/blood/article/132/Supplement%201/3311/264792/Baricitinib-Prevents-and-Treats-GvHD-through-Both ) -- John Broughton (♫♫) 18:48, 27 April 2020 (UTC)[reply]

The summary should mention this drug is only for hospitalized covid-19 patients, not for outpatients(treatment at home)

Now it takes several minutes to find this important information from this very long article.

The very end of the article finally tells:

"In May 2022, the FDA approved use of baricitinib for the treatment of adult patients hospitalized with COVID-19 who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation with a recommended dose of 4 mg once daily for 14 days or until hospital discharge, whichever happens first".

Is it a bad idea to use this drug for outpatients?

ee1518 (talk) 09:32, 26 September 2022 (UTC)[reply]

Can we relate the structure to its pharmacological properties

Needs summary of clinical trials, side-effects etc

See also New article on The Lancet

Another possible use

The summary should mention this drug is only for hospitalized covid-19 patients, not for outpatients(treatment at home)